Home
Mouse Anti-Human IgG2 Fc-BIOT (31-7-4)

Mouse Anti-Human IgG2 Fc-BIOT (31-7-4)

Name: Mouse Anti-Human IgG2 Fc-BIOT (31-7-4)
SKU: 9060-08
Price: 193 USD
Availability: InStock

Cat. No.:

9060-08

Biotin Anti-Human IgG₂ Fc antibody for use in ELISA, flow cytometry, immunocytochemistry, western blot, ELISpot, and multiplex assays.

$193.00

Size	Price (USD)	Quantity
0.5 mg	$193.00

Qty

Technical Bulletin Safety Datasheet

ELISA plate was coated with purified human IgG<sub>1</sub>, IgG<sub>2</sub>, IgG<sub>3</sub>, and IgG<sub>4</sub>. Immunoglobulins were detected with serially diluted Mouse Anti-Human IgG<sub>2</sub> Fc-BIOT (SB Cat. No. 9060-08) followed by Streptavidin

ELISA plate was coated with purified human IgG₁, IgG₂, IgG₃, and IgG₄. Immunoglobulins were detected with serially diluted Mouse Anti-Human IgG₂ Fc-BIOT (SB Cat. No. 9060-08) followed by Streptavidin

Product Specifications

More Information
Clone	31-7-4
Isotype	Mouse (BALB/c) IgG₁κ
Isotype Control	Mouse IgG1-BIOT (15H6)
Specificity	Human IgG₂ Fc
Immunogen	Human IgG₂ myeloma protein
Conjugate	BIOT (Biotin)
Buffer Formulation	Phosphate buffered saline containing < 0.1% sodium azide
Clonality	Monoclonal
Concentration	0.5 mg/mL
Volume	1.0 mL
Recommended Storage	2-8°C
Applications	ELISA – Quality tested ^2-12 FLISA – Quality tested ELISpot – Reported in literature ¹³ Flow Cytometry – Reported in literature ^15-17 Immunocytochemistry – Reported in literature ¹ Western Blot – Reported in literature ^6,14 Multiplex – Reported in literature ^7,18-22 Note – For direct immunostaining of IgG₂ positive cells in flow cytometry applications, clone HP6002 (SB Cat. No. 9070) is recommended
RRID Number	AB_2796634
Gene ID	3501 (Human)
Gene ID Symbol	IGHG2 (Human)
UniProt ID	P01859 (Human
UniProt Name	IGHG2_HUMAN (Human)

Documentation

Technical Bulletin Safety Datasheet

Certificate of Analysis Lookup

Enter the Catalog Number and Lot Number for the Certificate of Analysis you wish to view

Need help with this product?

Email technical support

or call 800.722.2255

Other Conjugates and Formulations

Citations

1. Conley ME, Brown P, Bartlet MS. IgG subclass potential of surface IgM-negative and surface IgM-positive human peripheral blood B cells. Clin Immunol Immunopathol. 1987;43:211-22. (Immunogen, ICC)
2. Arnold M, Zacher T, Dechant M, Kalden JR, Doxiadis II, Spriewald BM. Detection and specification of noncomplement binding anti-HLA alloantibodies. Hum Immunol. 2004;65:1288-96. (ELISA)
3. Bogdanos D, Baum H, Okamoto M, Montalto P, Sharma UC, Rigopoulou EI, et al. Primary biliary cirrhosis is characterized by IgG3 antibodies cross-reactive with the major mitochondrial autoepitope and its Lactobacillus mimic. Hepatology. 2005;42:458-65. (ELISA)
4. Whary MT, Sundina N, Bravo LE, Correa P, Quinones F, Caro F, et al. Intestinal helminthiasis in Colombian children promotes a Th2 response to Helicobacter pylori: possible implications for gastric carcinogenesis. Cancer Epidemiol Biomarkers Prev. 2005;14:1464-9. (ELISA)
5. Njoku DB, Mellerson JL, Talor MV, Kerr DR, Faraday NR, Outschoorn I, et al. Role of CYP2E1 immunoglobulin G4 subclass antibodies and complement in pathogenesis of idiosyncratic drug-induced hepatitis. Clin Vaccine Immunol. 2006;13:258-65. (ELISA)
6. Bogdanos D, Pusl T, Rust C, Vergani D, Beuers U. Primary biliary cirrhosis following Lactobacillus vaccination for recurrent vaginitis. J Hepatol. 2008;49:466-73. (ELISA, WB)
7. Arnold M, Dechant M, Doxiadis II, Spriewald BM. Prevalence and specificity of immunoglobulin G and immunoglobulin A non-complement-binding anti-HLA alloantibodies in retransplant candidates. Tissue Antigens. 2008;72:60-6. (ELISA, Multiplex)
8. Pratt-Riccio LR, Sallenave-Sales S, de Oliveira-Ferreira J, da Silva BT, Guimarães ML, Santos F, et al. Evaluation of the genetic polymorphism of Plasmodium falciparum P126 protein (SERA or SERP) and its influence on naturally acquired specific antibody responses in malaria-infected individuals living in the Brazilian Amazon. Malar J. 2008;7:144. (ELISA)
9. Xue L, Johnson R, Gorovits B. Prevalence and isotypic complexity of the anti-Chinese hamster ovary host cell protein antibodies in normal human serum. AAPS J. 2010;12:98-106. (ELISA)
10. Pratt-Riccio LR, Bianco C Jr, Totino PR, Perce-Da-Silva Dde S, Silva LA, Riccio EK, et al. Antibodies against the Plasmodium falciparum glutamate-rich protein from naturally exposed individuals living in a Brazilian malaria-endemic area can inhibit in vitro parasite growth. Mem Inst Oswaldo Cruz. 2011;106 Suppl 1:34-43. (ELISA)
11. Geisler WM, Morrison SG, Doemland ML, Iqbal SM, Su J, Mancevski A, et al. Immunoglobulin-specific responses to Chlamydia elementary bodies in individuals with and at risk for genital chlamydial infection. J Infect Dis. 2012;206:1836-43. (ELISA)
12. Chu SY, Yeter K, Kotha R, Pong E, Miranda Y, Phung S, et al. Suppression of rheumatoid arthritis B cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fcγ receptor IIb inhibitory receptor. Arthritis Rheumatol. 2014;66:1153-64. (ELISA)
13. Lue C, Tarkowski A, Mestecky J. Systemic immunization with pneumococcal polysaccharide vaccine induces a predominant IgA₂ response of peripheral blood lymphocytes and increases of both serum and secretory anti-pneumococcal antibodies. J Immunol. 1988;140:3793-800. (ELISPOT)
14. Bogdanos D, Pares A, Baum H, Caballeria L, Rigopoulou EI, Ma Y, et al. Disease-specific cross-reactivity between mimicking peptides of heat shock protein of Mycobacterium gordonae and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis. J Autoimmun. 2004;22:353-62. (WB)
15. Jackson AM, Lucas DP, Melancon JK, Desai NM. Clinical relevance and IgG subclass determination of non-HLA antibodies identified using endothelial cell precursors isolated from donor blood. Transplantation. 2011;92:54-60. (FC)
16. Jackson AM, Kuperman MB, Montgomery RA. Multiple hyperacute rejections in the absence of detectable complement activation in a patient with endothelial cell reactive antibody. Am J Transplant. 2012;12:1643-9. (FC)
17. Toyoda C, Suzuki Y, Tsuneyama H, Onodera T, Masuno A, Yabe R, et al. Production of human monoclonal anti-Jk3, recognising an epitope including the Jk^a/Jk^b polymorphic site of the Kidd glycoprotein. Transfus Med. 2014;24:286-91. (FC)
18. Hönger G, Hopfer H, Arnold M, Spriewald BM, Schaub S, Amico P. Pretransplant IgG subclasses of donor-specific human leukocyte antigen antibodies and development of antibody-mediated rejection. Transplantation. 2011;92:41-7. (Multiplex)
19. Lowe D, Higgins R, Zehnder D, Briggs DC. Significant IgG subclass heterogeneity in HLA-specific antibodies: Implications for pathogenicity, prognosis, and the rejection response. Hum Immunol. 2013;74:666-72. (Multiplex)
20. Arnold M, Ntokou I, Doxiadis II, Spriewald BM, Boletis JN, Iniotaki AG. Donor-specific HLA antibodies: evaluating the risk for graft loss in renal transplant recipients with isotype switch from complement fixing IgG1/IgG3 to noncomplement fixing IgG2/IgG4 anti-HLA alloantibodies. Transpl Int. 2014;27:253-61. (Multiplex)
21. Schaub S, Hönger G, Koller MT, Liwski R, Amico P. Determinants of C1q binding in the single antigen bead assay. Transplantation. 2014;98:387-93. (Multiplex)
22. Lefaucheur C, Viglietti D, Bentlejewski C, van Huyen JD, Vernerey D, Aubert O, et al. IgG donor-specific anti-human HLA antibody subclasses and kidney allograft antibody-mediated injury. J Am Soc Nephrol. 2016;27:293-304. (Multiplex)